Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …

Heart failure (HF) affects up to over 20% of patients with type 2 diabetes (T2DM), even more
in the elderly. Although, in T2DM, both hyperglycemia and the proinflammatory status …

The management of patients with diabetes mellitus (DM) in the era of the COVID-19
pandemic can be challenging. Even if they are not infected, they are at risk of dysregulated …

Cancer and cardiovascular disorders are known as the two main leading causes of mortality
worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related …

Peripheral artery disease (PAD) affects more than 230 million people worldwide. PAD
patients suffer from reduced quality of life and are at increased risk of vascular complications …

Macrovascular disease is tightly associated with obesity-induced metabolic syndrome.
Sitagliptin (SIT), an orally stable selective inhibitor of Dipeptidyl peptidase-4 (DPP-4), has …

Endothelial dysfunction, associated with depressed nitric oxide (NO) bioavailability, is a well-
recognized contributor to both accelerated atherogenesis and microvascular complications …

Introduction Ras guanine nucleotide-releasing protein-4 (RasGRP4) is an activator of Ras
protein, which plays significant roles in both the inflammatory response and immune …

Background: Oxidative stress is a hallmark of many diseases. A growing body of evidence
suggests that hyperglycemia-induced oxidative stress plays an important role in pancreatic β …

We previously reported that the circulatory level of Asymmetric dimethylarginine (ADMA), an
endogenous competitive inhibitor of nitric oxide synthase, was increased in diabetic kidney …